Biotechnology · Langhorne, Pennsylvania, United States
$5.58
-0.45% (-$0.02)2026-08-24
Smart-Money SignalNeutral · 46/100— Insiders are net sellers over 90 days (-$2.2M, 13 sales vs 8 buys)
Net Income-$40.2M
EPS$-0.31
Market Cap$1.1B
Price Performance
Historical data including institutional events
Company Profile
M
Matthew Pauls
CEO & Executive Director
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
The companyâs lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
